Appointment of change in management under Regulation 30 of SEBI (LODR) Regulations, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
In a single board meeting on April 16, 2025, Chemo Pharma Laboratories carried out a near-complete overhaul of its leadership team. The company appointed Ruchit Mehta as the new Managing Director and CEO, Utsav Trivedi as CFO, Bhawna Rajput as Company Secretary, and Sarvagya Goel and Shilpi Chopra as Non-Executive Independent Directors. At the same time, it accepted resignations from the outgoing CEO Bhavin Sheth, outgoing CFO and Executive Director Ashok Somani, three independent directors (Mathura Prasad Sharma, Toby Antony, Nandkumar Pareek), one non-executive director (Shanta Somani), and the previous Company Secretary (Unnatti Jain). All new appointments are external candidates and none are related to existing directors or KMP. Shareholder approval is pending for the executive and director appointments.
This is an unusually sweeping leadership change covering virtually all key managerial positions at once, which signals a significant strategic reset. Investors should watch for clarity on the reasons behind the mass exits and the new management's business direction, as such wide-scale turnover can create short-term uncertainty but also opens the door for a fresh growth strategy.